Ontology highlight
ABSTRACT:
SUBMITTER: Wang H
PROVIDER: S-EPMC10587833 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Wang Hua H Zhang Hengwei H Srinivasan Venkat V Tao Jianguo J Sun Wen W Lin Xi X Wu Tao T Boyce Brendan F BF Ebetino Frank H FH Boeckman Robert K RK Xing Lianping L
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20191119 2
Bortezomib (Btz) is a proteasome inhibitor approved by the FDA to treat multiple myeloma. It also increases bone volume by promoting osteoblast differentiation and inhibiting osteoclastogenesis in mice. However, Btz has severe systemic adverse effects, which would limit its use as a bone anabolic agent. Here, we designed and synthesized a bone-targeted form of Btz by conjugating it to a bisphosphonate (BP) with no antiresorptive activity. We report that BP-Btz inhibited osteoclast formation and ...[more]